Status:
UNKNOWN
Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)
Lead Sponsor:
Medical University of Vienna
Conditions:
Acute Renal Failure
Infection
Eligibility:
All Genders
19-70 years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to study the pharmacokinetics of anidulafungin during continuous venovenous hemofiltration. Background: Anidulafungin is a cyclic lipopeptide antifungal agent of the echi...
Eligibility Criteria
Inclusion
- Age 19 to 70 years
- Suspected or proven infection requiring parenteral antifungal therapy.
- Continuous venovenous hemofiltration because of an acute renal failure.
Exclusion
- Known history of hypersensitivity to echinocandins.
- An expected survival of less than three days.
- Known alcohol dependency, epilepsy, pregnancy or liver failure.
- Neutropenic patients
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00892359
Start Date
April 1 2009
Last Update
May 4 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090